Protein Design Labs Announces Positive Results in Phase II Trial of Zenapax For the Treatment of Acute Graft
Versus Host Disease
FREMONT, Calif., March 8 /PRNewswire/ -- Protein Design Labs, Inc. (PDL,
the "Company") (Nasdaq: PDLI) today announced that Zenapax(R) (daclizumab) has
demonstrated efficacy in patients with acute graft versus host disease (GVHD)
in a Phase II trial. The results were presented at the 1999 Tandem Bone
Marrow Transplant Meeting in Keystone, Colorado on March 6, 1999, by
investigator Nancy A. Kernan, M.D., Associate Attending Physician on the Bone
Marrow Transplantation Service at Memorial Sloan-Kettering Cancer Center.
The trial examined two dosing schedules of Zenapax in forty-three
allogeneic bone marrow transplant recipients with advanced or steroid
refractory GVHD. The first twenty-four patients were treated with Zenapax at
1 mg/kg on days 1, 8, 15, 22 and 29. The complete response rate was 29% on
day 43, and 29% of the patients survived to day 120. An additional
19 patients were treated with Zenapax at 1 mg/kg on days 1, 4, 8, 15 and 22.
In these patients, the complete response rate on day 43 was 47%, and survival
on day 120 was 53%. The complete response rates by organ involved with GVHD
were 73% for skin, 70% for the gut and 17% for liver. There were no serious
side effects attributed to Zenapax. (snip) |
